References
- World Health Organization. Global Tuberculosis Report 2016. World Health Organization, Geneva 2016.
- Centers for Disease Control and Prevention. Tuberculosis (TB) disease: only the tip of the Iceberg. [cited 2017 Aug]. Available from: http://www.cdc.gov/tb/publications/infographic/pdf/flyer-tuberculosis-disease-only-the-tip-of-the-iceberg-8.5x11.pdf.
- Venturini E, Tersigni C, Chiappini E, et al. Optimizing the management of children with latent tuberculosis infection. Expert Rev Anti Infect Ther. 2017;16:1–9.
- Ritz N, Curtis N. Novel concepts in the epidemiology, diagnosis and prevention of childhood tuberculosis. Swiss Med Wkly. 2014;144:14000.
- European Centre for Disease Prevention and Control (ECDC) Evidence Brief. Tuberculosis in Europe: from passive control to active elimination. [cited 2017 Aug]. Available from: http://ecdc.europa.eu/en/publications/publications/tuberculosis-evidence-brief-low-high-incidence-countries.pdf
- American Academy of Pediatric, Tuberculosis. In: Kimberlin DW, Brady MT, Kackson MA, et al. editors. Red Book: 2015 report of the committeeon infectious diseases. 30thed. Elk Grove Village, IL: American Academy of Pediatrics; 2015. p. 804–830
- Getahun H, Matteelli A, Abubakar I, et al. Management of latent mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J. 2015;46:1563–1576.
- National Institute for Health and Care Excellence. Tuberculosis. NICE January 2016. [cited 2017 Aug]. Available from: https://www.nice.org.uk/guidance/ng33/resources/tuberculosis-1837390683589
- Gwee A, Coghlan B, Curtis N. Question 1: what are the options for treating latent TB infection in children? Arch Dis Child. 2013;98:468–474.
- Skinner D, Hesseling AC, Francis C, et al. It’s hard work, but it’s worth it: the task of keeping children adherent to isoniazid preventive therapy. Public Health Action. 2013;3:191–198.
- Cruz AT, Starke JR, Lobato MN. Old and new approaches to diagnosing and treating latent tuberculosis in children in low-incidence countries. Curr Opin Pediatr. 2014;26:106–113.
- Bright-Thomas R, Nadwani S, Smith J, et al. Effectiveness of 3 months of rifampicin and isoniazid chemoprophylaxis for the treatment of latent tuberculosis infection in children. Arch Dis Child. 2010;95:600–602.
- Spyridis NP, Spyridis PG, Gelesme A, et al. The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. Clin Infect Dis. 2007;45:715–722.
- Ena J, Valls V. Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis. Clin Infect Dis. 2005;40:670–676.
- Erkens CG, Slump E, Verhagen M, et al. Monitoring latent tuberculosis infection diagnosis and management in the Netherlands. Eur Respir J. 2016;47:1492–1501.
- Galli L, Lancella L, Tersigni C, et al. Pediatric tuberculosis in Italian children: epidemiological and clinical data from the italian register of pediatric tuberculosis. Int J Mol Sci. 2016;17.
- Chang SH, Nahid P, Eitzman SR. Hepatotoxicity in children receiving isoniazid therapy for latent tuberculosis infection. J Pediatric Infect Dis Soc. 2014;3:221–227.
- Wu SS, Chao CS, Vargas HJ, et al. Isoniazid related hepatic failure in children: A survey of liver transplantation centers. Transplantation. 2007;84:173–179.
- Centers for Disease Control and Prevention (CDC). Severe isoniazid associated liver injuries among person being treated for latent tuberculosis infection- United States, 2004-2008. MMWR Morb Mortal Wkly Rep. 2010;59:224–229.
- Center for Disease Control and Prevention (CDC). Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection. MMWR Morb Mortal Wkly Rep. 2012;61:80.
- Saukkonen JJ, Cohn DL, Jasmer RM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006;174:935–952.
- Marais BJ, Gie RP, Schaaf HS, et al. The natural history of childhood intra-thoracic tuberculosis: acritical review of literature from the pre-chemotherapy era. Int J Tuberc Lung Dis. 2004;8:392–402.
- Il portale dell’epidemiologia per la sanità pubblica. Centro nazionale di Epidemiologia, Sorveglianza e Promozione della salute. Accessed 2017 Aug. Available at: www.epicentro.it
- Leeb S, Buxbaum C, Fischler B. Elevated transaminases are common in children on prophylactic treatment for tuberculosis. Acta Paediatr. 2015;104:479–484.
- Centers for Disease Control and Prevention. TB in specific population. [cited 2017 Aug]. Available from: http://www.cdc.gov/tb/topic/populations/tbinchildren/.
- Nicholson EG, Geltemeyer AM, Smith KC. Practice guideline for treatment of latent tuberculosis infection in children. J Pediatr Health Care. 2015;29:302–307.
- Cruz AT, Ahmed A, Mandalakas AM, et al. Treatment of latent tuberculosis infection in children. J Pediatric Infect Dis Soc. 2013;2:248–258.
- Cruz AT, Starke JR. Twice-weekly therapy for children with tuberculosis infection or exposure. Int J Tuberc Lung Dis. 2013;17:169–174.